KRAS Inhibitors Market is Set for Expansion During the Forecast Period (2026-2036) Supported by Emerging Therapies Targeting Diverse KRAS Mutations | DelveInsight
The KRAS inhibitors market is expected to experience strong growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline consisting of therapies such as Divarasib (RG6330; Roche/Chugai/Genentech), Olomorasib (LY3537982; Eli Lilly and Company), MK-1084...
Covered in this story
Call it yourself
No calls on $ROG.SW yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Roche Holding →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.